Johnson & Johnson ( J&J ) Comunica a sus Accionistas y Analistas del Sector ... Su Estrategia Oncologica asi como sus Planes de Registro 2013 / 2017 en los que Incluye al Yondelis para Sarcoma y Ovario en EEUU . A Robust Oncology Portfolio .

J&J Sees 10 Products Submitted for Approval by 2017 .

Emerging Markets


J&J  is Targeting some of the Biggest Markets and Diseases that Currently have few Treatment Options in its Growth Plan.
The Company plans to File for Approval by 2017 of Medicines including Simeprevir for Hepatitis C, Ibrutinib and Daratumumab for Blood Cancers, Yondelis 2nd line Soft Tissue Sarcoma , Sirukumab and Guselkumab for diseases of the Immune System and Vaccines for Influenza, Rabies and Polio.

New Medicines are Expected to Account for Almost Half of the Company’s Pharmaceutical Sales by 2017.
PRODUCTS IN REGISTRATION OR PLANNED FILINGS 2013-2017 :

 Planned Filing : 

***  Daratumumab .

***  Ibrutinib .

***  Siltuximab .

***  VELCADE® (EU) .

***  YONDELIS® (US) 2nd Line Soft Tissue Sarcoma .

***  ZYTIGA® (EU) .

********************************

 ADDITIONAL LINE EXTENSIONS OR NMEs UNDER DEVELOPMENT :

*** Daratumumab :Frontline multiple myeloma /// Frontline multiple myeloma, transpla.nt /// Frontline multiple myeloma, non-transplant /// Relapsed refractory multiple myeloma /// Smoldering multiple myeloma .

*** Ibrutinib :  Diffuse large B-cell lymphoma, frontline  /// Mantle cell lymphoma, frontline /// Multiple myeloma relapsed/refractory .

*** YONDELIS® (US) : Ovarian cancer .

*** ZYTIGA® :Metastatic breast cancer .

*** Siltuximab : multiple myeloma .


*****************************


*.- Our Strategic Path to Growth in Oncology .
*.- Established a Presence .
*.- Focused on Disease and Built Robust Portfolio .
*.- Building on Our Leadership Positions .
*.- Increasing Investment and Commercial Success .
*.- Disease Expertise Best Science and Innovation Transformational Drugs .

...